Your browser doesn't support javascript.
loading
Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England.
Webster, H H; Nyberg, T; Sinnathamby, M A; Aziz, N Abdul; Ferguson, N; Seghezzo, G; Blomquist, P B; Bridgen, J; Chand, M; Groves, N; Myers, R; Hope, R; Ashano, E; Lopez-Bernal, J; De Angelis, D; Dabrera, G; Presanis, A M; Thelwall, S.
Afiliação
  • Webster HH; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Nyberg T; MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • Sinnathamby MA; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Aziz NA; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Ferguson N; NIHR Health Protection Research Unit for Modelling and Health Economics, MRC Centre for Global Infectious Disease Analysis, Jameel Institute, Imperial College London, London, UK.
  • Seghezzo G; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Blomquist PB; UKHSA Outbreak Surveillance Team, London, UK.
  • Bridgen J; UKHSA Outbreak Surveillance Team, London, UK.
  • Chand M; UKHSA Genomics and Public Health Analysis, London, UK.
  • Groves N; UKHSA Genomics and Public Health Analysis, London, UK.
  • Myers R; UKHSA Genomics and Public Health Analysis, London, UK.
  • Hope R; UKHSA COVID-19 National Epidemiology Cell, London, UK.
  • Ashano E; UKHSA HCAI, Fungal, AMR, AMU & Sepsis Division, London, UK.
  • Lopez-Bernal J; UKHSA COVID-19 Surveillance Cell, London, UK.
  • De Angelis D; NIHR Health Protection Research Unit for Respiratory Infections, London, UK.
  • Dabrera G; MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • Presanis AM; UKHSA Statistics, Modelling and Economics Department, London, UK.
  • Thelwall S; UKHSA Joint Modelling Team, London, UK.
Nat Commun ; 13(1): 6053, 2022 10 13.
Article em En | MEDLINE | ID: mdl-36229438
The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 (n = 984,337) in a large cohort study in England. We estimated the risk of hospital attendance, hospital admission or death using multivariable stratified proportional hazards regression models. After adjustment for confounders, BA.2 cases had lower or similar risks of death (HR = 0.80, 95% CI 0.71-0.90), hospital admission (HR = 0.88, 95% CI 0.83-0.94) and any hospital attendance (HR = 0.98, 95% CI 0.95-1.01). These findings that the risk of severe outcomes following infection with BA.2 SARS-CoV-2 was slightly lower or equivalent to the BA.1 sub-lineage can inform public health strategies in countries where BA.2 is spreading.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article